CD19 UCAR-T cells

CD19 UCAR-T cells are an allogeneic, "off-the-shelf" chimeric antigen receptor (CAR) T-cell therapy designed to target the CD19 antigen expressed on B-lymphocytes. Developed by the Institute of Hematology & Blood Diseases Hospital at the Chinese Academy of Medical Sciences, these universal CAR-T cells are engineered from healthy donor T-cells. To minimize the risk of graft-versus-host disease (GvHD) and host rejection, the cells typically undergo genetic modification (such as CRISPR/Cas9 or TALEN-mediated knockout) to eliminate the endogenous T-cell receptor (TCR) and potentially HLA molecules. The therapy aims to achieve deep and rapid depletion of pathogenic B-cells, providing a therapeutic "reset" for patients with severe and refractory autoimmune diseases. It is currently being evaluated in clinical trials for conditions including systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM), and ANCA-associated vasculitis (AAV).

Other names

CD19 universal chimeric antigen receptor T-cellsCD-19 universal chimeric antigen receptor T-cellsCD 19 universal chimeric antigen receptor T-cellsAllogeneic CD19 CAR-T cellsUniversal CD19 CAR-T cells